• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Telesis Bio Reports First Quarter 2024 Financial Results

    5/9/24 4:05:00 PM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TBIO alert in real time by email

    SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the first quarter of 2024. 

    In discussing results, recently appointed President and CEO Eric Esser said, "I am pleased with our performance as we execute against our strategy to focus on Gibson SOLA and BioXp mRNA solutions. Our BioXp mRNA offerings continue to gain traction and are delivering real improvements in speed and simplicity to our customers in their discovery workflows. I'm also excited about the progress we've made with Gibson SOLA to ready it for commercial delivery, and believe it will transform high-throughput on-demand synthesis of high-fidelity DNA and mRNA in ways that will give our customers ultimate control and flexibility."

    Recent Highlights

    • The Company recently announced a new strategic focus enabled by the commercial availability of its groundbreaking Gibson SOLA platform. Going forward, the Company will increasingly concentrate its efforts on expanding the adoption of Gibson SOLA for both DNA and mRNA drug discovery applications.

       
    • BioXp automation platform sales driven by mRNA continue to increase, and in the first quarter of 2024, 40% of the customers who purchased instruments indicated that mRNA will be their primary workflow. The Company believes it has a highly differentiated offering with significant advantages over existing solutions and believes we are gaining traction in this market segment.

       
    • The strategic research collaboration and license agreement with Pfizer continues to progress favorably. This program is based upon Telesis' proprietary Gibson SOLA platform which utilizes enzymatic DNA synthesis technology for potential application by Pfizer in mRNA-based vaccines and other biopharma products.

       
    • First quarter 2024 operating expense, which is now better aligned with our current commercial strategy, is reduced 31% from the first quarter of the prior year.



    Summary of First Quarter 2024 Financial Results

    Revenue for the three months ended March 31, 2024 was $3.4 million compared to $6.3 million for the three months ended March 31, 2023. The decrease of $2.9 million was attributable to a decrease in product revenue of $1.7 million, a decrease in collaboration revenue of $1.0 million, and a decrease in service revenue of $0.4 million partially offset by an increase in royalty and other revenue of $0.2 million. Product revenue from BioXp capital equipment instruments decreased by $1.6 million, and revenue from BioXp kits decreased by $0.1 million. Service revenue decreases were largely driven by turnover of the commercial team at our Eton subsidiary. Collaboration revenue decreases were driven by the completion of deferred revenue amortization during the fourth quarter of 2023 for the $8.0 million up-front payment from our Pfizer contract.

    For the first quarter of 2024, gross margin percentage was 42% compared to 56% of total revenues for the three months ended March 31, 2023. The decrease was primarily due to a reduction in revenue from higher margin collaboration research programs, and a greater number of the higher margin BioXp 9600 systems sold during the first quarter of 2023, compared to the first quarter of 2024.

    Operating expense for the first quarter of 2024 was $10.0 million, a $4.5 million or 31% reduction from the first quarter of 2023 level of $14.5 million. A restructuring program in the fourth quarter of 2023 largely resulted in the year-over-year reduction. With respect to operating expense levels by income statement category, each of research & development, sales & marketing, and general & administrative expense contributed to the favorable year-over-year quarterly comparison.

    Net loss was $8.6 million for the first quarter of 2024, compared to a loss of $11.1 million in the same period in the prior year. Net loss per share was $5.52 for the first quarter of 2024, compared to $6.75 for the corresponding prior year period, with both periods adjusted for our 1-for-18 reverse stock split.

    As of March 31, 2024, cash, cash equivalents, restricted cash, and investments were $15.7 million compared to $19.3 million on December 31, 2023. Long-term notes payable was $5.2 million on March 31, 2024.  

    The Company will not be issuing forward-looking financial guidance at this time.

    About Telesis Bio

    Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity's greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com. Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.

    Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding Telesis Bio's future financial performance as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our most recently filed Annual Report on Form 10-K which was filed with the Securities and Exchange Commission on March 29, 2024. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.

    Contact:

    William J. Kullback

    Chief Financial Officer

    [email protected]





    Telesis Bio Inc.

    Selected Statements of Operations Financial Data

    (in thousands, except per share amounts)

    (unaudited)

     Three Months Ended 

    March 31,
     
     2024  2023 
    Revenue:     
    Product sales$1,264  $3,001 
    Service revenue 1,251   1,674 
    Collaboration revenue —   962 
    Royalties and other revenue 925   679 
    Total revenue 3,440   6,316 
    Cost of revenue 1,994   2,805 
    Gross Profit 1,446   3,511 
    Operating expenses:     
    Research and development 2,925   5,121 
    Sales and marketing 1,675   3,807 
    General and administrative 5,367   5,554 
    Total operating expenses 9,967   14,482 
    Loss from operations (8,521)  (10,971)
    Interest income 228   390 
    Interest expense (217)  (639)
    Change in fair value of derivative liabilities —   140 
    Other expense, net (125)  (36)
    Provision for income taxes (2)  (3)
    Net loss$(8,637) $(11,119)
    Less: redeemable convertible preferred stock dividends (585)  — 
    Net loss attributable to common stockholders$(9,222) $(11,119)
    Net loss per share attributable to common stockholders—basic and diluted$(5.52) $(6.75)
    Weighted average common stock outstanding—basic and diluted 1,670,981   1,647,945 





    Telesis Bio Inc.


    Selected Balance Sheet Financial Data

    (in thousands)

    (unaudited)

     March 31,  December 31, 
     2024  2023 
    Balance Sheet Data:     
    Cash, restricted cash, cash equivalents and short-term investments$15,696  $19,333 
    Working capital 16,983   22,167 
    Total assets 63,331   70,411 
    Total liabilities 41,682   40,873 
    Redeemable convertible preferred stock 29,885   29,300 
    Accumulated deficit (170,102)  (161,465)
    Total stockholders' (deficit) equity (8,236)  238 



    Primary Logo

    Get the next $TBIO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TBIO

    DatePrice TargetRatingAnalyst
    8/4/2021$45.00 → $38.00Neutral
    Roth Capital
    8/3/2021$19.00 → $38.00Market Perform
    SVB Leerink
    8/3/2021Outperform → Market Perform
    William Blair
    7/26/2021$28.00 → $45.00Buy
    Roth Capital
    More analyst ratings

    $TBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Krueger Todd was granted 8,390 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      7/26/24 4:07:04 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Golub Steven J was granted 8,390 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      7/26/24 4:06:35 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Hlavinka Sarah E. was granted 8,390 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      7/26/24 4:06:03 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Translate Bio with a new price target

      Roth Capital reiterated coverage of Translate Bio with a rating of Neutral and set a new price target of $38.00 from $45.00 previously

      8/4/21 10:08:32 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SVB Leerink reiterated coverage on Translate Bio with a new price target

      SVB Leerink reiterated coverage of Translate Bio with a rating of Market Perform and set a new price target of $38.00 from $19.00 previously

      8/3/21 11:37:09 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Translate Bio downgraded by William Blair

      William Blair downgraded Translate Bio from Outperform to Market Perform

      8/3/21 11:20:22 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Telesis Bio Reports Second Quarter and First Half 2024 Financial Results

      SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, today announced financial results for the second quarter and first half of 2024. Highlights Gibson SOLA – the Company continues to advance its Gibson SOLA reagent platform that enables on-premises automated overnight synthesis of high-fidelity long DNA and mRNA on a variety of liquid handling platforms. The Company's presentation "Enhancing Therapeutic Protein Production with Gibson SOLA Enzymatic DNA Assembly: Pioneeri

      8/7/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments
    • Telesis Bio Appoints William J. Kullback Chief Financial Officer

      SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023. As CFO, Kullback will be responsible for the Company's financial planning and analysis, accounting, internal audit, tax, and treasury functions. "Bill's deep industry knowledge, operational expertise, and extensive financial experience make him ideally positioned to help lead us through the next phase of the Company's growth," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. "We are thrilled to welcome Bill to our team and excited to have another lead

      8/29/23 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Financials

    Live finance-specific insights

    See more
    • Telesis Bio Reports First Quarter 2024 Financial Results

      SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the first quarter of 2024.  In discussing results, recently appointed President and CEO Eric Esser said, "I am pleased with our performance as we execute against our strategy to focus on Gibson SOLA and BioXp mRNA solutions. Our BioXp mRNA offerings continue to gain traction and are delivering real improvements in speed and simplicity to our customers in their discovery workflows. I'm also excited abo

      5/9/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results

      SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® kit sales, expanding gross margin and reduced operating expense. In discussing the results, Todd R. Nelson Ph.D., Founder and CEO of Telesis Bio said, "I'm pleased with our operating execution in a challenging macro environment during 2023. Our company experienced record BioXp kits sales and expanding gross margin aga

      3/28/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Reports Third Quarter 2023 Financial Results

      SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. "This quarter, we continued to drive adoption of our instruments and kits, make progress against important collaborations, advance our mRNA strategy, and strengthen both our Board of Directors and Management Team," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. Highlights Strengthened board of directors and management team: Appointed Greg Herrema, Senior Advisor to Novalis LifeSciences to the Telesis Bio board of directors in October 2023. Mr. Herrema's distinguished car

      11/13/23 4:22:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Telesis Bio Inc.

      SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)

      11/8/24 8:23:25 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Telesis Bio Inc.

      SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)

      11/6/24 4:50:27 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Telesis Bio Inc.

      SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)

      11/6/24 4:05:27 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Telesis Bio Inc.

      15-12G - Telesis Bio Inc. (0001850079) (Filer)

      1/14/25 4:35:26 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form EFFECT filed by Telesis Bio Inc.

      EFFECT - Telesis Bio Inc. (0001850079) (Filer)

      1/7/25 12:15:02 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form EFFECT filed by Telesis Bio Inc.

      EFFECT - Telesis Bio Inc. (0001850079) (Filer)

      1/7/25 12:15:03 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

      New technology has potential to accelerate timelines for therapeutic research and drug development Telesis Bio Inc. (OTC:TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced a new license agreement with Regeneron Pharmaceuticals, Inc. to deploy Telesis Bio's revolutionary Gibson SOLA™ platform at its R&D core facilities. This will help Regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs. Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson SOLA platform has been shown to e

      5/28/25 9:00:00 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis

      Telesis Bio, a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced that it has entered into a convertible preferred stock purchase agreement (the Purchase Agreement) to sell shares of a new series of convertible preferred stock in a private placement. The financing was led by Novalis LifeSciences and Northpond Ventures and is expected to result in gross proceeds to the Company of up to approximately $21 million. The Company's recently launched proprietary next-generation enzymatic synthesis platform, Gibson SOLA™, allows customers to take full control of their nucleic acid supply-chain,

      3/18/25 9:00:00 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis

      SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bio's Gibson SOLA enzymatic reagent platform running on Beckman Coulter Life Sciences automation to ensures rapid, reliable, and highly scalable production of extremely high-fidelity DNA, empowering researchers to achieve greater productivity and innovation in a wide array of discovery applications. The collaboration integrates Telesis Bio's Gibson

      9/25/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials